Key facts
- Schroders Capital is a other based in London, England with 24 tracked portfolio companies.
- Notable positions include Poolside (Software Development Applications), Wayve, Synthesia (Multimedia and Design Software), Neurona Therapeutics, Cera Care.
- Private Market View records 1 deal participation by Schroders Capital.
- Schroders Capital’s most recent recorded investment was in Aug 2025 and 1 over two years.
- The team roster lists 1 person.
- Schroders Capital reports $30.0B in regulatory assets under management across 66 private funds, per its SEC Form ADV (2026-03).
About Schroders Capital
Schroders Capital is a money management firm based in London, United Kingdom. Established in 1997, the firm offers specialized investment in private markets through primary, secondary, and co-investments. Its client base comprises institutional investors such as pension funds, insurance companies, family offices, and other financial institutions located in Europe, North America, and the Asia-Pacific region. It also specializes in fund-of-fund investments and seeks to invest in private equity and real assets globally. The assets of the firm are governed by the executive management team.
Registered with the SEC
Form ADV · 2026-03 · CRD 145194- Regulatory AUM
- $30.0B
- Private fund assets
- $14.5B
- Private funds
- 66 · 66 private equity
- Staff
- 163
- Registered office
- NEW YORK, NY
- SEC status
- Approved
Source: SEC Investment Adviser Public Disclosure, Form ADV (registered as SCHRODERS CAPITAL MANAGEMENT (US) INC.).
- ·The book's top 25 — of 24 recorded positions
- ·Every recorded deal — 1 rounds
- ·Watchlist + alerts for Schroders Capital's activity
Portfolio, priced
24 companies · by our current valuations| Company | Industry | Valuation | First invested | Role |
|---|---|---|---|---|
| Poolside (Software Development Applications) | Software Development Applications | $14.0B | — | |
| Wayve | Business/Productivity Software | $8.6B | — | |
| Synthesia (Multimedia and Design Software) | — | $3.9B | — | |
| Neurona Therapeutics | Drug Discovery | $1.1B | — | |
| Cera Care | — | $1.0B | — | |
| Eikon Therapeutics (NAS: EIKN) | — | $971.7M | — | |
| Bizongo | — | $818.2M | — | |
| Luminance | — | $400.0M | — | |
| tem (Business/Productivity Software) | — | $300.0M | — | |
| Artios | Drug Discovery | $260.3M | — | |
| AgroStar | — | $228.7M | — | |
| Kinaset Therapeutics | Drug Discovery | $186.0M | — | |
| HAYA Therapeutics | — | $115.5M | — | |
| Kainova Therapeutics | — | $92.0M | — | |
| Draig Therapeutics | — | $44.0M | — | |
| + 9 more companies · a free account shows the top of the book | ||||
Recent deals
1 recordedPartners, principals, and the people who answer a pitch. Pro members reveal contacts with credits.
Frequently asked
- What companies does Schroders Capital invest in?
- Schroders Capital has 24 recorded portfolio companies, including Poolside (Software Development Applications), Wayve, Synthesia (Multimedia and Design Software), Neurona Therapeutics.
- What is Schroders Capital's AUM?
- Schroders Capital manages approximately $111K in assets.
- Is Schroders Capital actively investing?
- Schroders Capital's most recent recorded investment was in Aug 2025.